QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS1-Region Domestic Shipping
What is TB-500?
TB-500 (Thymosin Beta-4 active fragment) in oral tablet form for GI absorption studies. The actin-binding LKKTETQ heptapeptide domain of Thymosin Beta-4, responsible for G-actin sequestration, cell migration promotion, angiogenesis, and anti-inflammatory cytokine modulation. Oral formulation enables gut-first-pass pharmacokinetic studies compared to parenteral administration. Research use only.
Research Applications
Oral TB-500 Bioavailability
GI stability, gastric acid resistance, intestinal absorption of actin-binding peptide
Oral vs Injectable PK Comparison
Serum TB-500 AUC, Cmax, Tmax — oral vs parenteral route comparison
Actin Polymerisation Research
G-actin sequestration, F-actin dynamics, cell cytoskeletal remodelling
Wound Healing (Oral Route)
Systemic delivery via oral route — wound closure, fibroblast migration
Anti-Inflammatory Oral Research
Oral TB-500 cytokine modulation, NF-κB suppression, systemic bioavailability
Quick Specs
| Form | Tablet — 500mcg per tablet, 100-tablet bottle |
| CAS Number | 107761-42-2 |
| Molecular Formula | C₂₁H₃₈N₈O₇S |
| Molecular Weight | 562.6 g/mol |
| Compound Type | Thymosin Beta-4 Fragment / Actin-Binding Recovery Peptide (Oral) |
| Purity | ≥99% by HPLC — every batch |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house synthesis — Qingdao, China |
| Storage | Room temperature sealed | cool, dry storage | protect from moisture |
| Shelf Life | 24 months unopened |
